Constella

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
18-07-2022
产品特点 产品特点 (SPC)
18-07-2022
公众评估报告 公众评估报告 (PAR)
30-11-2012

有效成分:

linaclotide

可用日期:

AbbVie Deutschland GmbH & Co. KG

ATC代码:

A06AX04

INN(国际名称):

linaclotide

治疗组:

Drugs for constipation

治疗领域:

Irritable Bowel Syndrome

疗效迹象:

Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.

產品總結:

Revision: 25

授权状态:

Authorised

授权日期:

2012-11-26

资料单张

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CONSTELLA 290 MICROGRAMS HARD CAPSULES
linaclotide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Constella is and what it is used for
2.
What you need to know before you take Constella
3.
How to take Constella
4.
Possible side effects
5.
How to store Constella
6.
Contents of the pack and other information
1.
WHAT CONSTELLA IS AND WHAT IT IS USED FOR
WHAT CONSTELLA IS USED FOR
Constella contains the active substance linaclotide. It is used to
treat the symptoms of moderate to severe
irritable bowel syndrome (often just called “IBS”) with
constipation in adult patients.
IBS is a common gut disorder. The main symptoms of IBS with
constipation include:

stomach or abdominal pain,

feeling bloated,

infrequent, hard, small or pellet-like stools (faeces).
These symptoms may vary from person to person.
HOW CONSTELLA WORKS
Constella acts locally in your gut, helping you to feel less pain and
less bloated, and to restore the normal
functioning of your bowels. It is not absorbed into the body, but
attaches to receptor called guanylate cyclase
C on the surface of your gut. By attaching to this receptor, it blocks
the sensation of pain and allows liquid to
enter from the body into the gut, thereby loosening the stools and
increasing your bowel movements.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CONSTELLA
DO NOT TAKE CONSTELLA
-
if you are allergic to linaclotide or any of the other ingredients of
this medicine (listed in se
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Constella 290 micrograms hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 290 micrograms of linaclotide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
White to off-white-orange opaque capsule (18 mm x 6.35 mm) marked
“290” with grey ink.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Constella is indicated for the symptomatic treatment of moderate to
severe irritable bowel syndrome with
constipation (IBS-C) in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is one capsule (290 micrograms) once daily.
Physicians should periodically assess the need for continued
treatment. The efficacy of linaclotide has been
established in double-blind placebo-controlled studies for up to 6
months. If patients have not experienced
improvement in their symptoms after 4 weeks of treatment, the patient
should be re-examined and the benefit
and risks of continuing treatment reconsidered.
_Special populations_
_Patients with renal or hepatic impairment_
No dose adjustments are required for patients with hepatic or renal
impairment (see section 5.2).
_Elderly patients_
For elderly patients, although no dose adjustment is required, the
treatment should be carefully monitored
and periodically re-assessed (see section 4.4).
_Paediatric population _
The safety and efficacy of Constella in children aged 0 to18 years
have not yet been established. No data are
available.
This medicinal product should not be used in children and adolescents
(see sections 4.4 and 5.1).
Method of administration
Oral use. The capsule should be taken at least 30 minutes before a
meal (see section 4.5).
4.3
CONTRAINDICATIONS
3
Hypersensitivity to linaclotide or to any of the excipients listed in
section 6.1.
Patients with known or suspected mechanical gastrointestinal
obstruction.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Constella should be used after organic diseases have
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 18-07-2022
产品特点 产品特点 保加利亚文 18-07-2022
公众评估报告 公众评估报告 保加利亚文 30-11-2012
资料单张 资料单张 西班牙文 18-07-2022
产品特点 产品特点 西班牙文 18-07-2022
公众评估报告 公众评估报告 西班牙文 30-11-2012
资料单张 资料单张 捷克文 25-02-2022
产品特点 产品特点 捷克文 25-02-2022
公众评估报告 公众评估报告 捷克文 30-11-2012
资料单张 资料单张 丹麦文 18-07-2022
产品特点 产品特点 丹麦文 18-07-2022
公众评估报告 公众评估报告 丹麦文 30-11-2012
资料单张 资料单张 德文 18-07-2022
产品特点 产品特点 德文 18-07-2022
公众评估报告 公众评估报告 德文 30-11-2012
资料单张 资料单张 爱沙尼亚文 18-07-2022
产品特点 产品特点 爱沙尼亚文 18-07-2022
公众评估报告 公众评估报告 爱沙尼亚文 30-11-2012
资料单张 资料单张 希腊文 18-07-2022
产品特点 产品特点 希腊文 18-07-2022
公众评估报告 公众评估报告 希腊文 30-11-2012
资料单张 资料单张 法文 18-07-2022
产品特点 产品特点 法文 18-07-2022
公众评估报告 公众评估报告 法文 30-11-2012
资料单张 资料单张 意大利文 18-07-2022
产品特点 产品特点 意大利文 18-07-2022
公众评估报告 公众评估报告 意大利文 30-11-2012
资料单张 资料单张 拉脱维亚文 18-07-2022
产品特点 产品特点 拉脱维亚文 18-07-2022
公众评估报告 公众评估报告 拉脱维亚文 30-11-2012
资料单张 资料单张 立陶宛文 18-07-2022
产品特点 产品特点 立陶宛文 18-07-2022
公众评估报告 公众评估报告 立陶宛文 30-11-2012
资料单张 资料单张 匈牙利文 18-07-2022
产品特点 产品特点 匈牙利文 18-07-2022
公众评估报告 公众评估报告 匈牙利文 30-11-2012
资料单张 资料单张 马耳他文 18-07-2022
产品特点 产品特点 马耳他文 18-07-2022
公众评估报告 公众评估报告 马耳他文 30-11-2012
资料单张 资料单张 荷兰文 18-07-2022
产品特点 产品特点 荷兰文 18-07-2022
公众评估报告 公众评估报告 荷兰文 30-11-2012
资料单张 资料单张 波兰文 18-07-2022
产品特点 产品特点 波兰文 18-07-2022
公众评估报告 公众评估报告 波兰文 30-11-2012
资料单张 资料单张 葡萄牙文 18-07-2022
产品特点 产品特点 葡萄牙文 18-07-2022
公众评估报告 公众评估报告 葡萄牙文 30-11-2012
资料单张 资料单张 罗马尼亚文 18-07-2022
产品特点 产品特点 罗马尼亚文 18-07-2022
公众评估报告 公众评估报告 罗马尼亚文 30-11-2012
资料单张 资料单张 斯洛伐克文 18-07-2022
产品特点 产品特点 斯洛伐克文 18-07-2022
公众评估报告 公众评估报告 斯洛伐克文 30-11-2012
资料单张 资料单张 斯洛文尼亚文 18-07-2022
产品特点 产品特点 斯洛文尼亚文 18-07-2022
公众评估报告 公众评估报告 斯洛文尼亚文 30-11-2012
资料单张 资料单张 芬兰文 18-07-2022
产品特点 产品特点 芬兰文 18-07-2022
公众评估报告 公众评估报告 芬兰文 30-11-2012
资料单张 资料单张 瑞典文 18-07-2022
产品特点 产品特点 瑞典文 18-07-2022
公众评估报告 公众评估报告 瑞典文 30-11-2012
资料单张 资料单张 挪威文 18-07-2022
产品特点 产品特点 挪威文 18-07-2022
资料单张 资料单张 冰岛文 18-07-2022
产品特点 产品特点 冰岛文 18-07-2022
资料单张 资料单张 克罗地亚文 18-07-2022
产品特点 产品特点 克罗地亚文 18-07-2022

搜索与此产品相关的警报

查看文件历史